Analyst Cautions Investors On Overreacting To ‘Early-Stage’ Pfizer/Seagen Discussions
In a news article by the Wall Street Journal, Pfizer Inc (NYSE:PFE) is reportedly in early-stage talks to acquire Seagen Inc (NASDAQ:SGEN) for…
Why Reata Pharmaceuticals Shares Are Falling Monday?
According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately.
Shionogi’s COVID-19 Pill, Based On Similar Action Like Pfizer’s, Sees Around $2B In Annual Sales
Japanese pharmaceutical company Shionogi & Co Ltd's CEO believes its COVID-19, Xocova, pill can generate $2 billion in annual sales if it secures FDA approval.
The company expects U.S. approval by late 2024.
Biophytis Seeks Early Access Authorization For Its COVID-19 Treatment In France
Biophytis SA (NASDAQ:BPTS) has begun the early access application process in France for Sarconeos (BIO101) for the treatment of severe COVID-19.…
Iradimed Notifies Potential Issue With Certain Syringe Adapter Sets During Use
Iradimed Corporation (NASDAQ:IRMD) notified a potential issue with some 1057 Syringe Adapter Sets related to the syringe venting function during use.…
iRhythm’s Q4 Earnings Beat Expectations, Analysts Remain Bullish On Upcoming Catalysts
iRhythm Technologies Inc (NASDAQ:IRTC) reported Q4 FY22 revenue of $112.6 million, up 37.7% Y/Y beating the consensus of $110.26 million.…
FDA Slams Break On Fulcrum Therapeutics’ Sickle Cell Disease Study, Shares Plummet
The FDA verbally informed Fulcrum Therapeutics Inc (NASDAQ:FULC) that it has issued a full clinical hold regarding the Investigational New Drug (IND)…
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Novartis AG (NYSE:NVS) has decided to terminate the Collaboration and License Agreement with Pliant Therapeutics, Inc.(NASDAQ:PLRX), announced in 2019. Novartis told…
